Feature | August 20, 2012

Baylor Heart Hospital First in the World to Merge Two High-Tech Systems for AFib Therapy

Merging to result in reduced procedure time and higher likelihood of favorable outcome

August 20, 2012 — The Baylor Heart Hospital in Plano, Texas, recently became the first hospital in the world to merge two highly advanced technologies for atrial fibrillation (AF) therapy.

The procedure combined the use of multi-electrode mapping (MEM) software with the Epoch platform, making the full-service cardiovascular hospital the first in the world to do so. Introduced by Biosense Webster, the software allows the physician maneuvering a MEM-enabled catheter to acquire multiple mapping points simultaneously with a higher level of detail. The Epoch platform is an advanced computer-controlled technology that allows physicians to navigate within the patient's heart with robotic precision.

Merging these two technologies means higher levels of efficiencies in mapping and correcting the patient’s cardiac arrhythmias. J. Brian DeVille, M.D., FACC, FHRS, medical director of electrophysiology and an electrophysiologist on the medical staff of the Baylor Heart Hospital, said this first-in-the-world procedure is an important step to further advancing patient care in the arena of cardiac electrophysiology.

“The integration of these two technologies confirms the Heart Hospital Baylor Plano’s commitment to excellence in patient care and providing advanced treatment to our patients,” DeVille said. “Our goal is always to seek ways to further minimize risk to the patient, which then increases the probability of favorable outcomes.”

Mark Valentine, the hospital’s president, added, “The Heart Hospital is fully committed to improving patient outcomes and that involves implementing advanced technologies that will help us fulfill that goal. We consistently strive to be on the forefront when it comes to innovation because we know that ultimately that is what will serve our patients’ interests in positive ways and help us continue to provide safe, quality, compassionate care.”

For more information: www.thehearthospitalbaylor.com

Related Content

News | Cardiac Resynchronization Therapy Devices (CRT)| September 03, 2015
Sorin Group announced the start of patient enrollment in its TRIUMPH-CRT clinical trial in Europe.
CeRtiTuDe cohort study, cardiac resynchronization therapy, CRT-D, CRT-P, ESC 2015
News | Cardiac Resynchronization Therapy Devices (CRT)| September 03, 2015
Most patients with a cardiac resynchronization therapy (CRT) pacemaker would not benefit from the addition of a...
News | Atrial Fibrillation| September 01, 2015
The first-ever two-year outcomes from the Global Anticoagulant Registry in the Field - Atrial Fibrillation (GARFIELD-AF...
Medtronic, sudden cardiac death, SCD, DISCOVERY, Oregon SUDS, study, ICDs, gene
News | Sudden Cardiac Arrest| August 31, 2015
Medtronic plc announced first-of-its-kind findings from two independent studies that have identified a gene associated...
News | Heart Failure| August 28, 2015
August 28, 2015 — BioControl Medical said it has completed enrollment in its INOVATE-HF (INcrease Of VAgal TonE in He
BioSig Technologies, research agreement, UCLA, Pure EP System, EP lab, ventricular tachycardia model, VT
Technology | EP Lab| August 20, 2015
BioSig Technologies announced it has signed a sponsored research agreement with the regents of the University of...
Biotronik, BioCONTINUE study, CRT-D, defibrillator, cardiac resynchronization therapy device, heart failure, first replacement
News | Cardiac Resynchronization Therapy Devices (CRT)| August 17, 2015
Biotronik announced that the first patient has been enrolled in the BioCONTINUE clinical trial (BIOtronik study to...
CMS, additional participants, Bundled Payments for Care Improvement initiative, Medicare, eipsodes of care
News | Business| August 17, 2015
The Centers for Medicare & Medicaid Service (CMS) announced that over 2,100 healthcare facilities have agreed to...
Overlay Init